Home › Funds › Venrock Adviser, LLC › DNTH

Venrock Adviser, LLC position in DNTH

DIANTHUS THERAPEUTICS INC · Health Care

Venrock Adviser, LLC reported holding 1,180,000 shares of DNTH (DIANTHUS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$115.0M, representing 3.49% of its reported portfolio and ranking #5 among its reported holdings. Venrock Adviser, LLC has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.18M sh
Reported value held$115.03M
Portfolio Weight3.49%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Venrock Adviser, LLC's DNTH position evolved

Venrock Adviser, LLC first disclosed a stake in DNTH in Q3 2023 at 927,706 shares (US$12.7M). The position peaked in Q2 2026 at 1,180,000 shares, worth US$115.0M. Across 12 filings, Venrock Adviser, LLC increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 1,180,000 shares valued at US$115.0M. Notable position changes include a 126% increase in Q1 2024 (shares fell 14% over the following quarter), a 43% trim in Q2 2025 (shares rose 111% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 927.71K $12.68M New
Q4 2023 927.71K $9.65M Hold
Q1 2024 2.09M $62.83M Add
Q2 2024 2.09M $54.20M Hold
Q3 2024 1.74M $47.76M Reduce
Q4 2024 1.74M $38.03M Hold
Q1 2025 1.74M $31.64M Hold
Q2 2025 1.00M $18.63M Reduce
Q3 2025 960.80K $37.81M Reduce
Q4 2025 1.00M $41.21M Add
Q1 2026 1.18M $99.03M Add
Q2 2026 1.18M $115.03M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Fairmount Funds Management LLC (US$247.3M), Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has Venrock Adviser, LLC held DNTH?

Venrock Adviser, LLC has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Venrock Adviser, LLC's current position in DNTH?

As of Q2 2026, Venrock Adviser, LLC holds 1.18M shares of DNTH (DIANTHUS THERAPEUTICS INC), valued at $115.03M, representing 3.49% of its reported portfolio and ranking #5.

Has Venrock Adviser, LLC been buying or selling DNTH?

In the latest 13F filing (Q2 2026), Venrock Adviser, LLC held unchanged its position in DNTH. The position peaked in Q2 2026 at 1.18M shares.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Fairmount Funds Management LLC, Avidity Partners Management LP, Octagon Capital Advisors LP, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.